{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:24:00Z","timestamp":1794273840482,"version":"4.9.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA270252"],"award-info":[{"award-number":["R01CA270252"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["R37CA250661"],"award-info":[{"award-number":["R37CA250661"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    B cell maturation antigen (BCMA) has emerged as a prominent immunotherapeutic target in multiple myeloma (MM) due to its restricted expression on MM cells, plasma cells and mature B cells, with minimal presence in other normal tissues. In this study, we demonstrate through RNA sequencing and flow cytometry analyses of acute myeloid leukemia (AML) cell lines and primary patient samples that BCMA is also a relevant AML-associated antigen. Its robust surface expression on AML cells positions it as a promising candidate for targeted immunotherapy. Functionally, our findings indicate that BCMA in AML operates similarly to its role in MM \u2013 engaging the NF-kB pathway upon ligand binding, thereby activating gene expression programs that support leukemia cell survival and proliferation. We assessed several BCMA-targeted immunotherapeutic strategies, including bispecific T-cell engagers (TCE) and chimeric antigen receptor (CAR) transduced T-cells, NK-cells, and macrophages. We found that TCE treatment and BCMA CAR engineering markedly improved effector cell mediated cytotoxicity against AML cells, underscoring BCMA\u2019s potential as a viable therapeutic target in AML. Furthermore, BCMA- directed TCE therapy significantly augmented the anti-leukemic activity of adoptively transferred CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cells in a human AML xenograft model. Taken together, these findings support BCMA as a novel immunotherapeutic target in AML. Leveraging existing BCMA-directed treatments developed for MM could enable rapid clinical translation and broaden immunotherapy options for patients with AML.\n                  <\/jats:p>","DOI":"10.1186\/s13045-025-01741-y","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:19:20Z","timestamp":1761315560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia"],"prefix":"10.1186","volume":"18","author":[{"given":"Ashley","family":"Varkey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet","family":"Bariana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Batistick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cassella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaina","family":"Anuncio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Samimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"J. Vallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zephyr","family":"Hameem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvarinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tycko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar.","family":"F. Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuditta","family":"Mantile-Selvaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"S. Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"L. Zakrzewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"4","key":"1741_CR1","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005.","journal-title":"Leukemia"},{"issue":"12","key":"1741_CR2","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","volume":"21","author":"S Xu","year":"2001","unstructured":"Xu S, Lam K-P. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol. 2001;21(12):4067\u201374.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"1741_CR3","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1309\/UJUL60UPUP3YJE93","volume":"126","author":"SE Gibson","year":"2006","unstructured":"Gibson SE, Dong HY, Advani AS, Hsi ED. Expression of the B cell\u2013associated transcription factors PAX5, OCT-2, and BOB. 1 in acute myeloid leukemia: associations with B-cell antigen expression and myelomonocytic maturation. Am J Clin Pathol. 2006;126(6):916\u201324.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"1741_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3109\/10428191003592735","volume":"51","author":"AS Advani","year":"2010","unstructured":"Advani AS, Lim K, Gibson S, et al. OCT-2 expression and OCT-2\/BOB. 1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma. 2010;51(4):606\u201312.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1741_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.18632\/oncotarget.109","volume":"1","author":"YN Demchenko","year":"2010","unstructured":"Demchenko YN, Kuehl WM. A critical role for the NFkB pathway in multiple myeloma. Oncotarget. 2010;1(1):59.","journal-title":"Oncotarget"},{"key":"1741_CR6","doi-asserted-by":"publisher","first-page":"1214095","DOI":"10.3389\/fimmu.2023.1214095","volume":"14","author":"C Guldenpfennig","year":"2023","unstructured":"Guldenpfennig C, Teixeiro E, Daniels M. NF-kB\u2019s contribution to B cell fate decisions. Front Immunol. 2023;14:1214095.","journal-title":"Front Immunol"},{"issue":"11","key":"1741_CR7","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 2017;21(11):3205\u201319.","journal-title":"Cell Rep"},{"issue":"21","key":"1741_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120974","volume":"3","author":"HA Knaus","year":"2018","unstructured":"Knaus HA, Berglund S, Hackl H, et al. Signatures of CD8\u2009+\u2009T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018;3(21):e120974.","journal-title":"JCI Insight"},{"key":"1741_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98960","author":"B Francois","year":"2018","unstructured":"Francois B, Jeannet R, Daix T, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.98960.","journal-title":"JCI Insight"},{"key":"1741_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732135","volume":"12","author":"EL Heipertz","year":"2021","unstructured":"Heipertz EL, Zynda ER, Stav-Noraas TE, et al. Current perspectives on off-the-shelf allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135.","journal-title":"Front Immunol"},{"issue":"1","key":"1741_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00435-w","volume":"12","author":"C Aparicio","year":"2023","unstructured":"Aparicio C, Acebal C, Gonz\u00e1lez-Vallinas M. Current approaches to develop off-the-shelf chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review. Exp Hematol Oncol. 2023;12(1):73.","journal-title":"Exp Hematol Oncol"},{"issue":"19","key":"1741_CR12","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO, et al. \u03b3-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585\u201397.","journal-title":"Blood"},{"issue":"6","key":"1741_CR13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.3390\/cancers14061459","volume":"14","author":"D L\u00e1inez-Gonz\u00e1lez","year":"2022","unstructured":"L\u00e1inez-Gonz\u00e1lez D, Serrano-L\u00f3pez J, Alonso-Dominguez JM. Understanding the notch signaling pathway in acute myeloid leukemia stem cells: from hematopoiesis to neoplasia. Cancers. 2022;14(6):1459.","journal-title":"Cancers"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01741-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:19:21Z","timestamp":1761315561000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01741-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1741"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01741-y","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}